Literature DB >> 30792209

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis.

Lenka Besse1, Andrej Besse2, Max Mendez-Lopez2, Katerina Vasickova3, Miroslava Sedlackova3, Petr Vanhara3, Marianne Kraus2, Jürgen Bader2, Renan B Ferreira4, Ronald K Castellano4,5, Brian K Law5,6, Christoph Driessen2.   

Abstract

Entities:  

Year:  2019        PMID： 30792209      PMCID： PMC6717569          DOI： 10.3324/haematol.2018.207704

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

Review 1.  The unfolded protein response and cellular senescence. A review in the theme: cellular mechanisms of endoplasmic reticulum stress signaling in health and disease.

Authors:  Olivier Pluquet; Albin Pourtier; Corinne Abbadie
Journal:  Am J Physiol Cell Physiol       Date:  2014-12-24       Impact factor: 4.249

2.  Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Authors:  Antonia Cagnetta; Michele Cea; Teresa Calimeri; Chirag Acharya; Mariateresa Fulciniti; Yu-Tzu Tai; Teru Hideshima; Dharminder Chauhan; Mike Y Zhong; Franco Patrone; Alessio Nencioni; Marco Gobbi; Paul Richardson; Nikhil Munshi; Kenneth C Anderson
Journal:  Blood       Date:  2013-07-03       Impact factor: 22.113

3.  Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Authors:  Patricia Maiso; Daisy Huynh; Michele Moschetta; Antonio Sacco; Yosra Aljawai; Yuji Mishima; John M Asara; Aldo M Roccaro; Alec C Kimmelman; Irene M Ghobrial
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

4.  Establishment of a system for monitoring endoplasmic reticulum redox state in mammalian cells.

Authors:  Kohsuke Kanekura; Shinsuke Ishigaki; Philip I Merksamer; Feroz R Papa; Fumihiko Urano
Journal:  Lab Invest       Date:  2013-09-16       Impact factor: 5.662

5.  Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.

Authors:  Silvia Nerini-Molteni; Marina Ferrarini; Sara Cozza; Federico Caligaris-Cappio; Roberto Sitia
Journal:  Br J Haematol       Date:  2008-03-12       Impact factor: 6.998

Review 6.  Myeloma today: Disease definitions and treatment advances.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2016-01       Impact factor: 10.047

7.  Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.

Authors:  Ann-Hwee Lee; Neal N Iwakoshi; Kenneth C Anderson; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-05       Impact factor: 11.205

8.  Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism.

Authors:  G P Soriano; L Besse; N Li; M Kraus; A Besse; N Meeuwenoord; J Bader; B Everts; H den Dulk; H S Overkleeft; B I Florea; C Driessen
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

9.  Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells.

Authors:  K K Starheim; T Holien; K Misund; I Johansson; K A Baranowska; A-M Sponaas; H Hella; G Buene; A Waage; A Sundan; G Bjørkøy
Journal:  Blood Cancer J       Date:  2016-07-15       Impact factor: 11.037

10.  Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Authors:  Dominik Dytfeld; Magdalena Luczak; Tomasz Wrobel; Lidia Usnarska-Zubkiewicz; Katarzyna Brzezniakiewicz; Krzysztof Jamroziak; Krzysztof Giannopoulos; Anna Przybylowicz-Chalecka; Blazej Ratajczak; Joanna Czerwinska-Rybak; Adam Nowicki; Monika Joks; Elzbieta Czechowska; Magdalena Zawartko; Tomasz Szczepaniak; Norbert Grzasko; Marta Morawska; Maciej Bochenek; Tadeusz Kubicki; Michalina Morawska; Katarzyna Tusznio; Andrzej Jakubowiak; MieczysÅ Aw Komarnicki
Journal:  Oncotarget       Date:  2016-08-30
View more
  21 in total

1.  miR-489 suppresses multiple myeloma cells growth through inhibition of LDHA-mediated aerobic glycolysis.

Authors:  Han Wu; Xiuhong Wang; Tingting Wu; Su Yang
Journal:  Genes Genomics       Date:  2019-12-23       Impact factor: 1.839

2.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 3.  Boron-Containing Compounds for Prevention, Diagnosis, and Treatment of Human Metabolic Disorders.

Authors:  Córdova-Chávez Ri; Carrasco-Ruiz Mf; Rodríguez-Vera D; Pérez-Capistran T; Tamay-Cach F; Scorei Ir; Abad-García A; Soriano-Ursúa Ma
Journal:  Biol Trace Elem Res       Date:  2022-06-30       Impact factor: 3.738

4.  Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.

Authors:  Ian D Ferguson; Yu-Hsiu T Lin; Christine Lam; Hao Shao; Kevin M Tharp; Martina Hale; Corynn Kasap; Margarette C Mariano; Audrey Kishishita; Bonell Patiño Escobar; Kamal Mandal; Veronica Steri; Donghui Wang; Paul Phojanakong; Sami T Tuomivaara; Byron Hann; Christoph Driessen; Brian Van Ness; Jason E Gestwicki; Arun P Wiita
Journal:  Cell Chem Biol       Date:  2022-07-18       Impact factor: 9.039

5.  Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.

Authors:  Tadeusz Kubicki; Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Magdalena Luczak; Krzysztof Lewandowski; Lidia Gil; Malgorzata Jarmuz-Szymczak; Dominik Dytfeld
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 6.  Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets.

Authors:  Daniela N Petrusca; Kelvin P Lee; Deborah L Galson
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

7.  Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death.

Authors:  Debora Soncini; Paola Minetto; Claudia Martinuzzi; Pamela Becherini; Valeria Fenu; Fabio Guolo; Katia Todoerti; Giovanni Calice; Paola Contini; Maurizio Miglino; Giulia Rivoli; Sara Aquino; Alida Dominietto; Antonia Cagnetta; Mario Passalacqua; Santina Bruzzone; Alessio Nencioni; Massimo Zucchetti; Tommaso Ceruti; Antonino Neri; Roberto M Lemoli; Michele Cea
Journal:  Blood Adv       Date:  2020-09-22

8.  The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.

Authors:  Brittany C Lipchick; Adam Utley; Zhannan Han; Sudha Moparthy; Dong Hyun Yun; Anna Bianchi-Smiraglia; David W Wolff; Emily Fink; Liang Liu; Cristina M Furdui; Jingyun Lee; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood Adv       Date:  2021-04-13

9.  Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.

Authors:  Lenka Besse; Andrej Besse; Sara C Stolze; Amin Sobh; Esther A Zaal; Alwin J van der Ham; Mario Ruiz; Santosh Phuyal; Lorina Büchler; Marc Sathianathan; Bogdan I Florea; Jan Borén; Marcus Ståhlman; Julia Huber; Arnold Bolomsky; Heinz Ludwig; J Thomas Hannich; Alex Loguinov; Bart Everts; Celia R Berkers; Marc Pilon; Hesso Farhan; Christopher D Vulpe; Herman S Overkleeft; Christoph Driessen
Journal:  Cancer Res       Date:  2021-06-22       Impact factor: 12.701

Review 10.  Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.

Authors:  Mélody Caillot; Hassan Dakik; Frédéric Mazurier; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.